Latest research

We speak to a neurologist about whether a future Covid-19 vaccine would be safe and effective for people with MS.

An update from the this ECTRIMS and ACTRIMS which is the largest annual MS research conference. 

The MS Trust is delighted that siponimod (Mayzent) has also been approved by NICE in England and Wales.

The MS Trust is delighted that siponimod (Mayzent) has been approved in Scotland for people with SPMS continuing to have relapses or show signs of MS activity on MRI scans.

Repairing the damage to nerves caused by MS is possible, according to research presented at the MS Virtual 2020 conference.

Health Technology Wales published a report supporting the routine use of autologous haematopoietic stem cell transplantation (AHSCT) for people with RRMS, who have recurrent symptoms despite treatment with disease modifying drugs.

We’ve been sifting through the research up to the end of June to bring you a round-up of the studies that give an idea of what coronavirus means to people with MS.

In its initial decision, Nice is unable to recommend siponimod (Mayzent) for active secondary progressive MS as an NHS treatment in England and Wales.

People with multiple sclerosis who contracted Covid-19 did no worse than the general population according to preliminary results from Italy.

In this study, researchers investigated whether people with MS gain cognitive benefits from learning a new language.

In this research, a programme designed to improve cognitive skills, such as memory, concentration and problem solving, was tested in a large clinical trial.

Ozanimod (Zeposia) has been recommended for licensing by the European Medicines Agency.